Back to Search
Start Over
Early Application of Bevacizumab After Sclerocorneal Grafting for Patients With Severe Late-Stage Ocular Chemical Burns.
- Source :
-
Cornea [Cornea] 2020 Jun; Vol. 39 (6), pp. 754-760. - Publication Year :
- 2020
-
Abstract
- Purpose: To investigate whether subconjunctival bevacizumab help prevent corneal graft neovascularization and prolong the graft survival of patients with chemical burns.<br />Methods: We performed a prospective nonrandomized comparative case series study. Twenty-six eyes received subconjunctival bevacizumab (10 mg/0.4 mL) once and topical immunosuppressive agents after sclerocorneal lamellar keratoplasty as the treatment, and 13 eyes received a topical immunosuppressant alone and served as the control group. The main outcomes were a cumulative probability of graft survival, development of corneal neovascularization, and complications.<br />Results: The postoperative follow-up time was 14.3 months (range, 2-62 mo). The cumulative graft survival time was significantly longer in the treatment group than that in the control group (42.9 ± 5.9 vs. 4.8 ± 0.7 mo; log rank < 0.001). In the treatment group, 19 of the 26 grafts (73.1%) survived as transparent with a mean follow-up of 18.7 ± 3.0 months. At the end of the follow-up, 4 grafts remained free of neovascularization, 2 developed edema without neovascularization, and 15 remained transparent with a stable ocular surface and some neovascular vessels in the peripheral transplant interface. The other 5 grafts became opaque and neovascularized. In the control group, all grafts became opaque and neovascularized within the follow-up period (5.5 ± 0.7 mo). During the follow-up, a corneal epithelial defect developed in 9 eyes in the treatment group and 7 in the control group.<br />Conclusions: Early application of subconjunctival bevacizumab after sclerocorneal lamellar keratoplasty can significantly prevent corneal neovascularization and promote graft survival for severe late-stage ocular chemical burns.
- Subjects :
- Administration, Topical
Adolescent
Adult
Angiogenesis Inhibitors administration & dosage
Burns, Chemical complications
Burns, Chemical diagnosis
Corneal Neovascularization diagnosis
Corneal Neovascularization etiology
Dose-Response Relationship, Drug
Eye Burns complications
Eye Burns diagnosis
Female
Follow-Up Studies
Graft Survival
Humans
Male
Middle Aged
Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors
Retrospective Studies
Time Factors
Time-to-Treatment
Trauma Severity Indices
Treatment Outcome
Young Adult
Bevacizumab administration & dosage
Burns, Chemical therapy
Corneal Neovascularization prevention & control
Corneal Transplantation methods
Eye Burns therapy
Sclera transplantation
Subjects
Details
- Language :
- English
- ISSN :
- 1536-4798
- Volume :
- 39
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Cornea
- Publication Type :
- Academic Journal
- Accession number :
- 32040009
- Full Text :
- https://doi.org/10.1097/ICO.0000000000002272